BIOA | Ticker Profile - Titan Protect

BIOA

BioAge Labs, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic · NMS

$15.70

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$753M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-7.85

Based on estimated future earnings — lower means cheaper

Rev Growth

+91.0%

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-26.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$52.00

+231% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 7 analysts covering this stock

About BioAge Labs, Inc.

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

https://bioagelabs.com

Country: United States Employees: 60 Industry: Drug Manufacturers - Specialty & Generic

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.683

Good returns relative to risk taken

Kelly Fraction

0.0521

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

-0.048

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-4.2%

Historical annualised return based on price data

Max Drawdown

-88.2%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$24.00

35% below the year high

52W Low

$3.88

305% above the year low

Avg Volume

489,518

Average daily shares traded — higher means easier to buy and sell

Short Ratio

4.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

4.3%

Low short interest — limited bearish positioning

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-2.40

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

1.06

Meaningful debt load — monitor closely

Current Ratio

24.76

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

24.38

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-915.4%

Profit from core operations before interest and tax

Free Cash Flow

$-58,337,752

Negative — the business is spending more than it generates

Revenue (TTM)

$10M

Total revenue over the last 12 months

Net Income

$-89,930,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$73.00

Target Median

$52.00

Target Low

$23.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go